Cardio Diagnostics Holdings (CDIO) Change in Taxes (2021 - 2022)

Cardio Diagnostics Holdings (CDIO) posted Change in Taxes of -$28000.0 for Q3 2022, down 156.0% sequentially from $50000.0 in Q2 2022.

Cardio Diagnostics Holdings (CDIO) Change in Taxes (2021 - 2022) Analysis & Trends

Cardio Diagnostics Holdings has reported Change in Taxes for 2 years, with the latest figure at -$28000.0 in Q3 2022.

Quarterly Change in Taxes changed N/A year-over-year to -$28000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $196434.0 (changed N/A YoY) and the FY2021 annual result came in at $124434.0, changed N/A from the prior year.
Change in Taxes fell to -$28000.0 in Q3 2022 per CDIO's latest filing, from $50000.0 in the prior quarter.
Over five years, Change in Taxes peaked at $124434.0 in Q4 2021 and troughed at -$28000.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	90.33 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Cardio Diagnostics Holdings	6.05 Mn	460,682.10	-	-

Download Data